CSBio CSBio

X
[{"orgOrder":0,"company":"PharmaMar","sponsor":"Immedica Pharma AB","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$2.1 million","newsHeadline":"PharmaMar Inks Pact with Immedica Pharma to market lurbinectedin in Eastern Europe and Other Territories ","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"PharmaMar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaMar Initiates First Human Clinical Trial of A New Molecule, PM534, For Cancer Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"PharmaMar"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ORYZON Announces First Patient In in FRIDA, a Phase Ib Trial With Iadademstat in Relapsed\/Refractory FLT3-mutant Acute Myeloid Leukemia Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Oryzon Genomics"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Grifols International","pharmaFlowCategory":"D","amount":"$77.4 million","upfrontCash":"$4.7 million","newsHeadline":"Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"VCN Biosciences"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synthetic Biologics Announces VCN Biosciences\u2019 VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"VCN Biosciences"},{"orgOrder":0,"company":"VCN Biosciences","sponsor":"Theriva Biologics","pharmaFlowCategory":"D","amount":"$4.7 million","upfrontCash":"Undisclosed","newsHeadline":"Synthetic Biologics Completes Acquisition of VCN Biosciences","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SPAIN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"VCN Biosciences"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1 with powerful differentiating effect in hematologic cancer. It is being investigated in with gilteritinib for relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation.

            Lead Product(s): Iadademstat,Gilteritinib Fumarate

            Therapeutic Area: Oncology Product Name: ORY-1001

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            PM534, a novel marine-derived anti-tumor compound, has been tested in the laboratory, both in cell cultures and in animals. In both cases, PM534 showed relevant antitumor activity in a wide variety of tumor types, including those with resistance to other chemotherapies.

            Lead Product(s): PM534

            Therapeutic Area: Oncology Product Name: PM534

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 30, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The acquisition transforms Synthetic Biologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, both of which are next-generation OVs in development for the treatment of cancers with high unmet need.

            Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

            Therapeutic Area: Oncology Product Name: VCN-01

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Theriva Biologics

            Deal Size: $4.7 million Upfront Cash: Undisclosed

            Deal Type: Acquisition March 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma.

            Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

            Therapeutic Area: Oncology Product Name: VCN-01

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Theriva Biologics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            VCN has the rights to four exclusive patents for proprietary technologies, including VCN-01, as well as technologies developed in collaboration with the Virotherapy Group of the Catalan Institute of Oncology (ICO-IDIBELL), with a number of additional patents pending.

            Lead Product(s): VCN-01,Gemcitabine,Paclitaxel

            Therapeutic Area: Oncology Product Name: VCN-01

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Grifols International

            Deal Size: $77.4 million Upfront Cash: $4.7 million

            Deal Type: Acquisition December 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Immedica gets an exclusive distribution and marketing right of the anti-tumor drug lurbinectedin for territories that include the UK, Ireland, the Nordic countries, Middle East and North Africa.

            Lead Product(s): Lurbinectedin

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Immedica Pharma AB

            Deal Size: Undisclosed Upfront Cash: $2.1 million

            Deal Type: Agreement April 29, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY